|
1
|
Avila MA, Berasain C, Sangro B and Prieto
J: New therapies for hepatocellular carcinoma. Oncogene.
25:3866–3884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Fuster J and Bruix J:
Barcelona-Clínic Liver Cancer Group: The Barcelona approach:
Diagnosis, staging and treatment of hepatocellular carcinoma. Liver
transplantation. 10(Suppl 1): S115–S120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan SH, Wu CW, LAF Y, Chi C-W and Lin WC:
miR-21 microRNA expression in human gastric carcinomas and its
clinical association. Anticancer Res. 28:907–911. 2008.PubMed/NCBI
|
|
7
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wienholds E and Plasterk RH: MicroRNA
function in animal development. FEBS Lett. 579:5911–5922. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu W, Mao SY and Zhu WY: Impact of tiny
miRNAs on cancers. World J Gastroenterol. 13:497–502. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Yao J, Shi X, Hu L, Li Z, Song T
and Huang C: MicroRNA-302b suppresses cell proliferation by
targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells.
BMC Cancer. 13:4482013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suzuki H, Maruyama R, Yamamoto E and Kai
M: Epigenetic alteration and microRNA dysregulation in cancer.
Front Genet. 4:2582013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heneghan HM, Miller N and Kerin MJ: MiRNAs
as biomarkers and therapeutic targets in cancer. Curr Opin
Pharmacol. 10:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwarzenbach H, Milde-Langosch K,
Steinbach B, Müller V and Pantel K: Diagnostic potential of
PTEN-targeting miR-214 in the blood of breast cancer patients.
Breast Cancer Res Treat. 134:933–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tömböl Z, Szabó PM, Molnár V, Wiener Z,
Tölgyesi G, Horányi J, Riesz P, Reismann P, Patócs A, Likó I, et
al: Integrative molecular bioinformatics study of human
adrenocortical tumors: MicroRNA, tissue-specific target prediction
and pathway analysis. Endocr Relat Cancer. 16:895–906. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang H, Kong W, He L, Zhao J-J, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al:
MicroRNA expression profiling in human ovarian cancer: MiR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shirahata A, Fan W, Sakuraba K, Yokomizo
K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et
al: MACC 1 as a marker for vascular invasive hepatocellular
carcinoma. Anticancer Res. 31:777–780. 2011.PubMed/NCBI
|
|
19
|
Karp X and Ambros V: Developmental
biology. Encountering microRNAs in cell fate signaling. Science.
310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and
Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic
cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Z, Chen S, Luan X, Li Y, Liu M, Li X,
Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical
cancers and inhibits the growth of HeLa cells. IUBMB Life.
61:1075–1082. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Humbert PO, Verona R, Trimarchi JM, Rogers
C, Dandapani S and Lees JA: E2f3 is critical for normal cellular
proliferation. Genes Dev. 14:690–703. 2000.PubMed/NCBI
|
|
23
|
Leone G, DeGregori J, Yan Z, Jakoi L,
Ishida S, Williams RS and Nevins JR: E2F3 activity is regulated
during the cell cycle and is required for the induction of S phase.
Genes Dev. 12:2120–2130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang L, Meng Y, Bao C, Liu W, Ma C, Li A,
Xuan Z, Shan G and Jia Y: Robustness and backbone motif of a cancer
network regulated by miR-17-92 cluster during the G1/S
transition. PLoS One. 8:e570092013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
DeGregori J: The Rb network. J Cell Sci.
117:3411–3413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lukas J, Herzinger T, Hansen K, Moroni MC,
Resnitzky D, Helin K, Reed SI and Bartek J: Cyclin E-induced S
phase without activation of the pRb/E2F pathway. Genes Dev.
11:1479–1492. 1997. View Article : Google Scholar : PubMed/NCBI
|
